Every material Form 8-K SPRUCE BIOSCIENCES, INC. has filed with the SEC since May 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Spruce Biosciences reported a third-quarter 2026 net loss of $24.0 million, or $(8.51) per share, up from $8.2 million, or $(14.58) per share, a year earlier. The company also separated its CRHX-101 program into a new subsidiary, Adrenyx Biosciences, and plans to distribute Adrenyx shares to Spruce stockholders, a step its board has not yet approved.
Q3 2026 net loss was $24.0 million, or $(8.51) per share, versus $8.2 million, or $(14.58) per share, in Q3 2025; R&D expenses were $18.1 million.
Cash and cash equivalents were $87.7 million at September 30, 2026, up from $48.9 million at December 31, 2025, which the company says will fund operations and debt obligations into the second half of 2027.
The Distribution of Adrenyx stock is expected in the first half of 2027, but Spruce's board has not yet approved it or set a record date.
Under an amended Avenue loan agreement dated November 6, 2026, up to $15.0 million of Tranche 2 may be drawn between January 1, 2027 and March 31, 2027.
Spruce Biosciences reported second-quarter 2026 results with a net loss of $16.2 million, or $(6.68) per share, compared with a net loss of $2.1 million in the second quarter of 2025. The company said it expects its cash to fund operations and debt obligations into the second half of 2027, and it reiterated plans for a BLA submission for TA-ERT in the fourth quarter of 2026.
Q2 2026 net loss was $16.2 million, or $(6.68) per share, versus $2.1 million in Q2 2025.
Research and development expenses were $12.2 million in Q2 2026, driven by TA-ERT manufacturing scale-up and clinical development.
Cash and cash equivalents were $96.3 million as of June 30, 2026, up from $48.9 million at December 31, 2025.
Dr. Adrian Quartel was appointed Chief Medical Officer effective July 27, 2026.
Spruce Biosciences appointed Adrian Quartel, M.D., as its Chief Medical Officer on July 27, 2026, replacing Dr. Kirk Ways, who had been serving as interim Chief Medical Officer. Dr. Ways will remain on the Company's Board of Directors. The filing describes Dr. Quartel's experience in pharmaceutical clinical development and rare disease launches, including prior Chief Medical Officer roles at Zevra Therapeutics, Acer Therapeutics and Adamas Pharmaceuticals.
Adrian Quartel, M.D., FFPM, appointed Chief Medical Officer on July 27, 2026
Replaces Dr. Kirk Ways, who had been Interim Chief Medical Officer
Dr. Ways will continue as a member of the Board of Directors
Dr. Quartel previously served as Chief Medical Officer of Zevra Therapeutics, Acer Therapeutics and Adamas Pharmaceuticals
Spruce Biosciences reported a first-quarter 2026 net loss of $12.3 million, or $(8.94) per share, down from $14.0 million, or $(23.95) per share, a year earlier, as operating expenses fell to $12.0 million from $14.5 million. The company closed a $69.0 million gross underwritten public offering on April 22, 2026, which included 1,150,000 shares, pre-funded warrants and 180,000 option shares, and reported preliminary, unaudited cash of $107.3 million as of April 30, 2026. Shareholders should note that the offering increases the share count, and the company's stated timeline for a BLA submission for TA-ERT is the fourth quarter of 2026.
Net loss of $12.3 million, or $(8.94) per share, for the quarter ended March 31, 2026, versus $14.0 million, or $(23.95) per share, a year earlier.
Total operating expenses of $12.0 million versus $14.5 million; R&D included $5.7 million in one-time product acquisition costs related to SPR202.
Cash and cash equivalents of $54.1 million at March 31, 2026, up from $48.9 million at December 31, 2025.
Closed $69.0 million in aggregate gross offering proceeds on April 22, 2026; preliminary, unaudited cash of $107.3 million as of April 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SPRUCE BIOSCIENCES, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →